The relative contribution of monoamine oxidase and cytochrome P450 lsozymes to the metabolic deamination of the trace amine tryptamine

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 2, 2003, Pages 539-546

  Yu, Ai Ming ^a   Granvil, Camille P ^a,e   Haining, Robert L ^b   Krausz, Kristopher W ^a   Corchero, Javier ^a,f   Küpfer, Adrian ^c   Idle, Jeffrey R ^d,g   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e Department of Preclinical Development and Formulations   (United States)

^f UNIVERSITY OF EXTREMADURA   (Spain)

^g National Institutes of Health Bldg ^*  (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CYTOCHROME P450; TRACE ELEMENT; TRYPTAMINE;

AMINO ACID METABOLISM; ARTICLE; CATALYSIS; DEAMINATION; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; HYDROXYLATION; IN SITU HYBRIDIZATION; LIVER MICROSOME; METABOLIC REGULATION; NEUROMODULATION; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEAMINATION; HUMANS; ISOENZYMES; MICROSOMES, LIVER; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; TRYPTAMINES;

EID: 0037310739     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.043786     Document Type: Article

References (30)

1. Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, and Schalling D (1989) Debrisoquine hydroxylation polymorphism and personality. Lancet 1:555.
2. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, et al. (2001) Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA 98:8966-8971.
3. 3H]1-Methyl-4-phenyl-2, 3-dihydropyridinium ion binding sites in mouse brain: pharmacological and biological characterization. J Neurochem 54:1905-1910.
4. Ding X and Kaminsky LS (2002) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol [epub ahead of print].
5. Evans WE and Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science (Wash DC) 286:487-491.
6. Fonne-Pfister R, Bargetzi MJ, and Meyer UA (1987) MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 148:1144-1150.
7. Gelboin HV, Krausz KW, Shou M, Gonzalez FJ, and Yang TJ (1997) A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism. Pharmacogenetics 7:469-477.
8. Gilham DE, Cairns W, Paine MJ, Modi S, Poulsom R, Roberts GC, and Wolf CR (1997) Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 27:111-125.
9. Granvil CP, Krausz KW, Gelboin HV, Idle JR, and Gonzalez FJ (2002) 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther 301:1025-1032.
10. Hiroi T, Imaoka S, and Funae Y (1998) Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 249:838-843.
11. Hiroi T, Kishimoto W, Chow T, Imaoka S, Igarashi T, and Funae Y (2001) Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 142:3901-3908.
12. 14C]-debrisoquine in man. Br J Clin Pharmacol 7:257-266.
13. Javors MA, Bembenek ME, Bowden CL, Abell CW, and Maas JW (1989) The effect of debrisoquin on MAO A and MAO B activities. Life Sci 45:2359-2364.
14. Jones RS (1981) In vivo pharmacological studies on the interactions between tryptamine and 5-hydroxytryptamine. Br J Pharmacol 73:485-493.
15. Jones RS (1982) Tryptamine: a neuromodulator or neurotransmitter in mammalian brain? Prog Neurobiol 19:117-139.
16. Kendler KS, Heninger GR, and Roth RH (1982) Influence of dopamine agonists on plasma and brain levels of homovanillic acid. Life Sci 30:2063-2069.
17. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, and Bertilsson L (1993) Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 87:23-28.
18. Madani S, Paine MF, Lewis L, Thummel KE, and Shen DD (1999) Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res (NY) 16:1199-1205.
19. Mahgoub A, Idle JR, Dring LG, Lancaster R, and Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586.
20. Martinez C, Agundez JA, Gervasini G, Martin R, and Benitez J (1997) Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics 7:85-93.
21. McFayden MC, Melvin WT, and Murray GI (1998) Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem Pharmacol 55:825-830.
22. Miller GP, Hanna IH, Nishimura Y, and Guengerich FP (2001) Oxidation of phenethylamine derivatives by cytochrome P450 2D6: the issue of substrate protonation in binding and catalysis. Biochemistry 40:14215-14223.
23. Neff NH and Yang HY (1974) Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs. Life Sci 14:2061-2074.
24. Ohta S, Tachikawa O, Makino Y, Tasaki Y, and Hirobe M (1990) Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer. Life Sci 46:599-605.
25. Siegle I, Fritz P, Eckhardt K, Zanger UM, and Eichelbaum M (2001) Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11:237-245.
26. Silas JH, Jones J, Tucker GT, Townshend MM, Phillips CA, and Smith AJ (1979) Dissociation of biochemical and hypotensive effects of debrisoquine in hypertensive patients. Eur J Clin Pharmacol 16:81-86.
27. Sullivan JL, Coffey CE, Basuk B, Cavenar JO, Maltbie AA, and Zung WW (1980) Urinary tryptamine excretion in chronic schizophrenics with low platelet MAO activity. Biol Psychiatry 15:113-120.
28. Sullivan JP, McDonnell L, Hardiman OM, Farrell MA, Phillips JP, and Tipton KF (1986) The oxidation of tryptamine by the two forms of monoamine oxidase in human tissues. Biochem Pharmacol 35:3255-3260.
29. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW, Kosel M, Eap CB, and Baumann P (2000) Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 855:235-243.
30. Yu A, Dong H, Lang D, and Haining RL (2001) Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab Dispos 29:1362-1365.